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This retrospective single institutional study of 628 consecutive al-
logeneic transplantation patients revealed some novel findings. PSC
were associated with a higher incidence of aGVHD, but not
cGVHD. The combination of FK/MTXwas associated with a lower
risk of cGVHD thanCSA/MTXand will need to be investigated fur-
ther. Validation of these findings requires large cooperative prospec-
tive studies.445
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AND CHRONIC GVHD AFTER MATCHED UNRELATED DONOR TRANS-
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Introduction: The inflammatory cytokine tumor necrosis factor-
a (TNFa) plays a central role in the pathogenesis of acute GVHD,
but its role in chronic GVHD is less clearly defined.We recently de-
scribed an association between the recipient TNFa gene polymor-
phisms and the severity of acute GVHD in pediatric unrelated
donor BMT (Goyal et al, Biol Blood Marrow Transplant, 2010). We
now report the correlative analyses between the recipient and donor
TNFa promoter region single nucleotide gene polymorphisms
(SNP) and the risk of acute and chronic GVHD in this cohort.
Materials and Methods: Genotyping was performed on pretrans-
plant genomic DNA samples from recipient-donor pairs (n 5
180). To address the confounding effect of population stratification,
significant associations were reanalyzed in white recipient-donor
pairs.
Results: Twenty-three patients died before day+100; 78/153 (51%)
of the remaining evaluable patients developed cGVHD with exten-
sive disease in 60/76 (79%) patients. Similar to findings in recipients,
the donor TNFa variant A allele of -863C/A SNP (HR 3.67, p 5
0.01) and the variant C allele of -1031T/C SNP (HR 2.85, p 5
0.05) were also associated with grade III-IV aGvHD. The recipient
TNFa variant A allele of - 238G/A SNP was associated with grade
II-IV aGVHD (HR 2.38; p\0.01, previously reported) as well
with cGVHD (RR 1.68; P 5 0.02). Six out of 44 (14%) patients
(14%) with variant -238A allele compare to 40/99 (40%) patients
without -238A allele did not develop acute or chronic GVHD.
The rates of only acute (16%, 18%) and only chronic GVHD
(18%, 19%) were similar in those with or without recipient -238A al-
lele, respectively. However, 23/44 (52%) patients with the -238A al-
lele developed both acute and chronic GVHD compared with 22/99
(22%) without the -238A allele (RR 2.35, p\0.01, Table 1). These
associations remained significant when analyzed in white-only re-
cipient-donor pairs. No statistically significant association was de-
tected between the donorTNFa gene polymorphisms and the risk of
cGVHD.
Table 1.
Recipient No Acute Only Only BothTNF alpha
-238 G>Aor Chronic
GVHDAcute
GVHDChronic
GVHDAcute & Chronic
GVHD P-ValueAA/AG 6/14 (14%) 7/44 (16%) 8/44 (18%) 23/44 (52%) <0.01GG 40/99 (40%) 18/99 (19%) 19/99 (19%) 22/99 (22%)Conclusions: In this large cohort of pediatricmatched unrelated do-
nor transplants: 1) The recipient and donor TNFa -863A allele and
-1031C allele are associated with grade III-IV aGvHD. 2) The recip-
ient TNFa -238A allele identifies a subset of patients who develop
both acute and chronicGVHD.These findings deserve further studyin independent cohorts and may be clinically relevant in a risk-ad-
justed approach toGVHDmanagement in pediatric unrelated donor
transplants.446
COMPARISON OF SIROLIMUS AND MYCOPHENOLATE MOFETIL AS SAL-
VAGE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE
Nishihori, T.1, Pidala, J.1, Kim, J.2, Tomblyn,M.1, Anasetti, C.1 1Moffitt
Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
Glucocorticoid refractory acute GVHD (aGVHD) is a major
source of mortality following allogeneic HCT. Comparative studies
to evaluate the efficacy of salvage immune suppressive agents are
lacking. We retrospectively compared the efficacy of sirolimus
(SIR) and mycophenolate mofetil (MMF) as salvage aGVHD ther-
apy for glucocorticoid refractory, dependent or intolerant patients.
Of 281 consecutive patients who received allogeneic HCT from
07/2004 to 09/2009, we identified 84 patients who received tacroli-
mus/methotrexate (Tac/MTX) GVHD prophylaxis, were treated
with glucocorticoids for grades 2-4 aGVHD, were refractory (n 5
72) or dependent (n 5 12) to glucocorticoids, and received 2nd
line GVHD treatment with MMF (n5 56) or SIR (n5 28). Demo-
graphics and treatment variables were similar except for year of
transplant (earlier for MMF). Disease diagnoses included AML (n
5 27), NHL (n 5 14), MDS (n 5 12), ALL (n 5 9), CML (n 5
7), CLL (n 5 4), SAA (n 5 2), MPD (n 5 5), MM/PCL (n 5 3),
and HL (n 5 1). Conditioning regimens were busulfan/fludarabine
for 71, and other regimens for 13. Except for 1 bone marrow graft
in each group, all received peripheral blood stem cells. Graft sources
were from HLA-matched siblings (35), or 8/8 HLA-matched unre-
lated donors (49). Overall grade distribution of aGVHD at time of
salvage for MMF vs. SIR was the following: grade 1 (13 vs. 2), grade
2 (31 vs. 16), grade 3 (9 vs. 5) and grade 4 (3 vs. 5). Median steroid
dose at the time of salvage was 1 (range 0.17 – 2.28) mg/kg for
MMF group and 1 (range 0.12 – 2.0) mg/kg for SIR group. Median
time from steroid to salvage was 20 (range 1 – 208) days for MMF
and 19 (range 1 – 275) days for SIR (p 5 0.84). Complete response
(CR) rates following initiation of MMF or SIR did not significantly
differ at the following time points: 1 week (MMF 30%, SIR 21%), 4
weeks (MMF 44%, SIR 46%), and 6 weeks (MMF 60%, SIR 58%).
Overall response rates (ORR) also did not differ significantly: 1 week
(MMF 57%, SIR 42%), 4 weeks (MMF 57%, SIR 77%), and 6 weeks
(MMF 72%, SIR 75%). Flare or progression of aGVHD while on
salvage regimen was noted in 50% (MMF) and 36% (SIR) of patients
(p5 0.64). Median overall survival from the time of salvage therapy
forMMF vs. SIR did not significantly differ, 11.6 (95%CI 7.0 – 28.1)
vs. 9.7 (95% CI 5.4 – 15.9) months, log-rank p5 0.88. These retro-
spective data suggest that MMF and SIR have comparable activity in
the treatment of steroid refractory or dependent acute GVHD.447
HUMAN MULTIPOTENT ADULT PROGENITOR CELLS EFFECTIVELY MOD-
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DUCING GVHD WHILE PRESERVING GRAFT-VERSUS-LEUKEMIA
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Metheny, L.L.1, Eid, S.3, Keller, M.3, Van Devort, A.2, Lee, Z.H.4,
Wilson, D.4, Auletta, J.2, Vant Hof, W.5, Paez, C.2, Cooke, K.R.2
1Case Western Reserve University, Cleveland, OH; 2University Hospitals
of Cleveland, Cleveland, OH; 3Case Western Reserve University, Cleve-
land, OH; 4National Center for Stem Cell and Regenerative Medicine,
Cleveland, OH; 5Athersys, Inc, Cleveland, OH
Graft-versus-host disease (GVHD) limits successful outcomes fol-
lowing allogeneic BMT (allo-BMT). The pathophysiology of
GVHD involves three distinct phases which contribute to inflamma-
tory cytokine dysregulation, the generation of cellular effectors, and
target organ injury. This framework uncovers opportunities to reg-
ulate GVHD. We examined whether reported immunosuppressive
and regenerative properties of human, bone marrow-derived
multi-potent, adult progenitor cells (hMAPCs) could regulate
GVHD using established murine models. The immuno-regulatory
Poster Session II S369capacity of MultiStem (Athersys, Inc), a commercial hMAPC
product, was first evaluated in vitro in a MLC of purified mouse den-
dritic and T cells. MultiStem inhibited mouse T-cell proliferation
in a reproducible, dose dependent fashion not observed with human
dermal fibroblasts. This effect was associated with reduced T cell ac-
tivation and inflammatory cytokine secretion and robust increases in
the concentrations of PGE2 and TGFb in cell culture supernatants.
Importantly, MultiStem had no effect on the generation CTL ac-
tivity in vitro. Similar findings were observed in vivo when Multi-
Stem was delivered in the context of allo-BMT using C57BL/6
and B6D2F1 mice as donors and recipients, respectively. Tail vein
injection ofMultiStem onDay +1 (D1) and +4 (D4) resulted in sig-
nificant reductions in splenic T cell expansion and in numbers of
TNFa and IFNg-producingCD4+ andCD8+ cells at D10 compared
to untreated allo controls. These findings were associated with re-
ductions in 1) D10 serum levels of TNFa and IFNg, 2) D10 intesti-
nal and hepatic inflammation and 3) systemicGVHDasmeasured by
survival and clinical score. Suppression of systemic GVHD was ob-
served in a dose dependent manner. Biodistribution studies using
bioluminescence and cryo-imaging showed that MultiStem
tracked from the lung and into the abdominal organs (liver and
spleen) within the first 4 days after injection. When GVL effects
were tested, the administration of MultiStem resulted in superior
leukemia free survival; MultiStem treated mice had less GVHD
but effectively eradicated tumor challenge. Collectively, these data
provide critical information regarding the biodistribution and regu-
latory capacity of human MultiStem in established models of
GVHD. Mechanistic studies are ongoing, which we anticipate will
be useful in optimizing the dose and schedule of MultiStem in on-
going, first-in-human clinical trials following allogeneic BMT.448
SEVERE DENTAL CARIES IN PATIENTS WITH ORAL CHRONIC GRAFT-
VERSUS-HOST DISEASE
Castellarin, P.3, Stevenson, K.2, Treister, N.1 1Dana-Farber/Brigham
and Women’s Cancer Center, Boston, MA; 2Dana-Farber Cancer Insti-
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Objective:The oral cavity is one of themost frequently affected sites
by cGVHD following allogeneic hematopoietic cell transplantation
(alloHCT), and can be a significant source of patient morbidity due
to bothmucosal and salivary gland involvement. The development of
dental decay is a potentially devastating oral complication that has
only rarely been reported in the transplantation literature. The pur-
pose of this study was to comprehensively characterize a cohort of
patients with cGVHD that subsequently developed extensive dental
caries.
Methods: A retrospective case-record review was conducted for pa-
tients who had undergone alloHCT at Dana-Farber/Brigham and
Women’s Cancer Center between 1990 and 2010 and developed
cGVHD-associated rampant dental decay. All patients underwent
dental evaluations before and after alloHCT that consisted of
a soft and hard tissue examination and dental radiographs. Caries di-
agnosed from the pre-alloHCT evaluation were treated definitively
such that all patients were considered free of caries at the time of ad-
mission for HCT.
Results: A total of 21 patients were identified with a median time of
cGVHDonset of 5.4months (range 2.2-18.5) post-alloHCT. All pa-
tients were diagnosed with oral cGVHD, with 90% demonstrating
mucosal involvement, and 95% with salivary gland involvement.
Post-alloHCT dental evaluation was performed at a median of 22
months (range 4-81) after alloHCT. when ten patients were diag-
nosed with gross caries and eight patients presented four or more af-
fected teeth. Cervical and interproximal patterns of dental caries
were frequently diagnosed. The proportion of patients with gross,
one surface, and greater than one surface caries, categorized as 0,
1-3, or $4, were significantly higher post-alloHCT compared to
pre-alloHCT with at least 50% of patients experiencing an increase.
Conclusions: Patients with oral cGVHD, who were free of caries at
the time of transplantation, developed extensive areas of cervical de-
cay in amedian time of less than two years post-alloHCT. This is the
first comprehensive characterization of this severe late complication
of alloHCT and oral cGVHD. Greater awareness on the part oftransplant oncologists and dentists as well asmore aggressive preven-
tive measures are warranted, as well as prospective studies to better
elucidate the incidence of this complication, identify risk factors,
and evaluate the effectiveness of preventive interventions.449
IN VIVO REFLECTANCE CONFOCAL MICROSCOPY IN THE EARLY DIAGNO-
SIS OF ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE: A PILOT
STUDY
Corbin, J.M., MacDonald, A., Purdy, K.S., Webb, A., Pasternak, S.,
Couban, S., Langley, R.G. Dalhousie University, Halifax, NS, Canada
Background: Graft-versus-host disease (GVHD) is a common and
potentially life-threatening complication of allogeneic hematopoi-
etic stem cell transplantation. The diagnosis of cutaneous GVHD
can be challenging, as it is based on clinical presentation, which often
simulates other processes. Early recognition and treatment are es-
sential to reduce the associated morbidity and mortality. Reflectance
confocal microscopy (RCM) is a high-resolution, noninvasive tech-
nique that may facilitate a timely diagnosis and prompt institution
of treatment.
Objective: We sought to describe the features of acute cutaneous
GVHD under RCM and to correlate these with the histopathologi-
cal findings.
Methods: Patients were recruited prospectively to undergo clinical
and RCM examination. A total of 19 patients were enrolled, five of
whom developed acute cutaneous GVHD following an allogeneic
hematopoietic stem cell transplant. RCM images from these five
cases were examined and the key confocal features were compared
to histopathological findings.
Results:OnRCMexamination, features of acute cutaneousGVHD,
such as apoptotic keratinocytes, inflammatory cell infiltration and in-
terface dermatitis, were identified and were shown to correlate well
with histopathological findings.
Limitations: The open-label, unblinded nature of this study allows
for potential observer bias and the small sample size may not reflect
the findings in a larger population. The sensitivity and specificity of
RCM in this population remain to be determined.
Conclusion: The findings support further examination of the use of
RCM in the rapid, bedside diagnosis of acute cutaneous GVHD.450
SIGNIFICANT ADVERSE EFFECTS ASSOCIATED WITH SIROLIMUS/TACRO-
LIMUS GVHD PROPHYLAXIS REGIMEN (SIRO-tac) IN ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANT (alloHSCT) PATIENTS (pts): A
SINGLE INSTITUTION EXPERIENCE
Nathan, S., Maciejewski, J.J., Rich, E.S., Gregory, S.A., Schultz, K.,
Fung, H.C. Rush University Medical Center, Chicago, IL
Background: On account of the increased transplant related mor-
bidity and mortality with the use of methotrexate (MTX) based im-
munosuppressive therapy we adopted a new policy in GVHD
prophylaxis using a combination of tacrolimus and sirolimus abort-
ing the use ofMTX.We report the adverse effects that were noted in
our patients who underwent a related or un-related AlloHSCT
transplantation.
Patients and Methods: Data from 46 consecutive AlloHSCT pts
over a 2 year period were reviewed. 39 pts who received siro-tac
with or without ATG were identified. Demographics, indication
for transplantation, type of donor, conditioning regimen (CR),
GVHD prophylaxis associated complications were identified and
collected.
Results: 46 pts underwent an alloHSCT at our institution from
2009-11. 39 (84.78%) pts (average age 44 yrs, range 20-65 yrs) re-
ceived Siro-tac with or without ATG and all without MTX. 21
(53.84%) pts were male and 18 (46.15%) pts female. Indications
for transplant included relapsed non-Hodgkin lymphoma, Hodgkin
lymphoma, acute myelogenous leukemia, acute and chronic lympho-
cytic leukemia, myelodysplastic syndrome and myelofibrosis. 15
(46.15%) pts received a myeloablative CR. 14 pts had an unrelated
